Prediction of changes in memory performance by plasma homovanillic acid levels in clozapine-treated patients with schizophrenia

By Sumiyoshi Tomiki   Roy A.   Kim C.-H.   Jayathilake K.   Lee M.   Sumiyoshi C.   Meltzer H.  

Psychopharmacology, Vol. 177, Iss. 1-2, 2004-12 ,pp. : 79-83

Springer Publishing Company

Access to resources Recommend Favorite

Clinical efficacy of clozapine in treatment-refractory schizophrenic patients

By Min-Soo L.   In-Kwa J.   Dong-Il K.  

European Neuropsychopharmacology, Vol. 5, Iss. 3, 1995-09 ,pp. : 342-342

Elsevier

Access to resources Recommend Favorite

Effects of clozapine on plasma monoamine metabolites in treatment-refractory schizophrenic patients

By Min-Soo L.   Seung-Hyun K.  

European Neuropsychopharmacology, Vol. 5, Iss. 3, 1995-09 ,pp. : 341-342

Elsevier

Access to resources Recommend Favorite

CYP1A2 activity is an important determinant of clozapine dosage in schizophrenic patients

By Doude van Troostwijk L.J.A.E.   Koopmans R.P.   Vermeulen H.D.B.   Guchelaar H.-J.  

European Journal of Pharmaceutical Sciences, Vol. 20, Iss. 4, 2003-12 ,pp. : 451-457

Elsevier

Access to resources Recommend Favorite

Steady-state Pharmacokinetics of Clozapine in Refractory Schizophrenic Saudi Arabian Patients

By Hussein R.   Gad A.   Raines D.A.   Chaleby K.   Al-Rawithi S.   El-Yazigi A.  

Pharmacy and Pharmacology Communications, Vol. 5, Iss. 7, 1999-07 ,pp. : 473-478

Pharmaceutical Press

Access to resources Recommend Favorite